ArticleClinical ophthalmology (Auckland, N.Z.)2026
Subconjunctival Triamcinolone Acetonide Injection Compared with Dexamethasone Ophthalmic Insert for Inflammation Prophylaxis After Cataract Surgery: A Comparative Clinical Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To determine differences in efficacy and outcomes during the first post-operative month (POM1) between intracanicular dexamethasone implant (DII) and subconjunctival triamcinolone injection (STAI) for prophylaxis of rebound iritis or cystoid macular edema (CME) in patients undergoing cataract surgery. Design: This was a retrospective, comparative cohort study of standard phacoemulsification with posterior-chamber intraocular lens placement between January 2020 and July 2023. Methods: Patients in the DII group received a 0.4 mg insert intraoperatively, whereas those in the STAI group received 4-6 mg of triamcinolone. Patients were excluded if they received additional anti-inflammatory treatment or a history of iritis, ocular infection, glaucoma, intraoperative posterior capsular rupture, vitreous prolapse, or retained lens fragments. Post-operative visits during POM1 were reviewed to determine the characteristics and timing of rebound iritis, CME, and changes in intraocular pressures (IOP). Results: In total, 266 eyes from 174 patients were included in the DII group, while 103 eyes from 62 patients were included in the STAI group. Demographics, comorbidities, and pre-operative IOPs were similar between groups. Neither group experienced an increase in IOP elevation of >10 mmHg from baseline or preoperative measurements compared to POM1. The DII group had mean time (days) to iritis that occurred sooner compared to the STAI group [DII group (12.8 days, SD: 8.3) vs STAI group (22.3 days, SD: 5.7), p < 0.05]. Overall, there was a trend toward higher rates of rebound iritis among the DII (9.0%) than among the STAI (3.9%) groups (p = 0.12). Conclusion: In this retrospective cohort study, participants who received STAI appeared to have iritis at a later onset than those who received DII. However, post-operative complications were low, with no significant differences in the rates of rebound iritis or CME between the two groups. STAI and DII have similar clinical utility in the prophylaxis of inflammation after cataract surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.